Views 323
Citations 0
News From the Food and Drug Administration
June 16, 2015

More Protection Against Plague

Author Affiliations

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(23):2312. doi:10.1001/jama.2015.6117

Moxifloxacin, a fluoroquinolone antibacterial agent, has been approved under the FDA’s Animal Efficacy Rule to treat patients with plague.

A rare and potentially fatal illness, plague is caused by infection with the Yersinia pestis bacteria, also considered a potential bioterrorism agent. The 3 most common forms of plague are bubonic (lymph node infection), pneumonic (lung infection), and septicemic (blood infection) (

First Page Preview View Large
First page PDF preview
First page PDF preview